Ovarian disorder

This study tests whether taking probiotic supplements can improve the gut and vaginal microbiome in women with advanced or recurrent ovarian cancer who are receiving platinum-based chemotherapy. About 161 participants will be randomly assigned to receive either probiotics or a pl…

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This trial tests whether two approved drugs, dabrafenib and trametinib, can treat rare cancers that have a specific genetic change called BRAF V600. These drugs are already used for melanoma and lung cancer, but researchers want to see if they help people with other cancer types.…

This phase 2 trial tests whether a patient's own white blood cells, genetically modified in a lab to recognize and attack their specific tumor mutations, can shrink metastatic cancers. Participants include people with several advanced solid tumors or multiple myeloma who have exh…

This early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…

This phase 1 trial investigates a new treatment for advanced ovarian cancer that has stopped responding to platinum chemotherapy. The therapy uses a patient's own immune cells, called T cells, which are genetically modified in a lab to recognize and attack a protein called TAG72 …

This early-stage trial tests a new mRNA cancer vaccine called CryptiVax-1001 in 50 women with advanced ovarian cancer. The vaccine is designed to train the immune system to recognize and attack cancer cells, potentially delaying or preventing the cancer from coming back. The main…

This early-stage trial is testing an experimental drug called SIM0505 in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check for any early signs that the drug shrinks tumors. About 414 participants will re…

This study tests a new drug called TUB-040 for people with ovarian cancer that no longer responds to platinum chemotherapy, or with a type of lung cancer that has come back. TUB-040 is an antibody-drug conjugate, meaning it delivers a powerful chemotherapy directly to cancer cell…

This study tests whether a combination of two drugs (avutometinib and defactinib) works better than standard treatments for people with recurrent low-grade serous ovarian cancer. About 270 participants whose cancer returned after platinum-based therapy will be randomly assigned t…

This study tests a new drug called raludotatug deruxtecan (R-DXd) in people whose high-grade serous ovarian, peritoneal, or fallopian tube cancer has returned after platinum chemotherapy. R-DXd is an antibody-drug conjugate that seeks out cancer cells and delivers a toxic payload…

This phase 3 trial tests whether a new drug, sacituzumab tirumotecan, given with or without bevacizumab, can help people with platinum-sensitive recurrent ovarian cancer live longer without their cancer worsening. About 770 participants who have already completed two rounds of ch…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.

This phase 2 trial tests whether adding an experimental immune-boosting drug (CDX-1140) to two standard immunotherapies (pembrolizumab and bevacizumab) can shrink tumors in people whose ovarian cancer has returned. About 80 adults with recurrent ovarian, fallopian tube, or perito…

This Phase 3 trial tests whether a targeted therapy called sacituzumab tirumotecan (Sac-TMT), given alone or with bevacizumab, can help people with advanced ovarian cancer live longer without their cancer growing. About 900 participants who have finished initial chemotherapy will…

This phase 3 trial compares a new drug called Rina-S to standard chemotherapy in 82 people with platinum-resistant ovarian cancer. Participants are randomly assigned to receive either Rina-S or one of four approved chemotherapies. The goal is to see if Rina-S can delay cancer gro…

This study tests whether giving the targeted drug mirvetuximab soravtansine together with standard chemotherapy (carboplatin) before surgery can shrink advanced ovarian, fallopian tube, or peritoneal cancers that have a specific protein (FRα). About 140 adults with stage III or I…

This early-stage trial tests two experimental drugs, XmAb541 and XmAb808, in people with advanced ovarian cancer that has come back or spread. The main goal is to see if the combination is safe and find the best dose. About 90 adults with a specific tumor marker (CLDN6) will take…

This study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…

This phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This study tests a new drug called LBL-024 combined with the chemotherapy paclitaxel in people with ovarian cancer that has become resistant to platinum-based treatments. The trial involves 110 participants and aims to see if the combination can shrink tumors and delay disease pr…

This study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…

This study tests a combination of two drugs, sacituzumab govitecan and cisplatin, in people with ovarian or endometrial cancer that has come back but still responds to platinum-based treatments. The goal is to find the safest dose and see how well the drugs shrink tumors. About 5…

This phase 2 trial is testing a drug called datopotamab deruxtecan (Dato-DXd), alone or with other cancer medicines, in people with advanced or metastatic solid tumours. The study includes seven cancer types and aims to see if the drug shrinks tumours and how safe it is. Around 4…

This study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…

This phase 2 trial is testing an experimental drug called ubamatamab, alone or combined with other cancer drugs, in 220 people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The study aims to see how…

This phase 3 study tests whether a new drug called azenosertib works better than standard chemotherapy for people with a specific type of ovarian cancer that no longer responds to platinum-based treatments. The trial enrolls 420 women whose tumors have a high level of a protein c…

This early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…

This study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…

This study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …

This phase 3 trial compares a once-weekly growth hormone injection (lonapegsomatropin) to a daily one (somatropin) in 186 prepubertal children with growth failure due to Turner syndrome, SHOX deficiency, being small for gestational age, or idiopathic short stature. The goal is to…

This trial is testing whether an experimental drug called TUB-040, when added to standard chemotherapy and a targeted therapy, is safe and tolerable for women with a specific type of advanced ovarian cancer. The study involves about 72 participants whose cancer has returned but s…

This early-phase study tests a new treatment called TNhYP218 CAR T cells for people with solid tumors that have high levels of a protein called mesothelin, including mesothelioma. Participants' own immune cells are collected, modified in a lab to better attack cancer, and then gi…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This study tests a new drug called AZD4956, alone or with other cancer drugs, in people with advanced or spreading solid tumors that have a specific DNA repair defect (HRR deficiency). The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. …

This study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …

This early-stage trial tests IM-1021, an antibody-drug conjugate designed to deliver a cancer-killing drug directly to tumor cells. It enrolls 117 adults with advanced solid tumors or B-cell lymphomas that have not responded to standard treatments. The main goals are to check saf…

This early-phase trial tests a new drug called BGB-B455 in about 90 people with advanced or metastatic solid tumors that have a specific protein (CLDN6). The main goals are to find a safe dose and see what side effects occur. The study has two parts: first finding the right dose,…

This early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This early-stage trial is testing an investigational drug called ARR-002 in adults with advanced or metastatic ovarian or endometrial cancer, including cases that have stopped responding to platinum-based chemotherapy. The main goals are to assess the drug's safety, tolerability,…

This early-phase trial tests a combination of two drugs—DS-8201a and olaparib—in people with advanced HER2-expressing cancers that have spread or cannot be removed. DS-8201a delivers chemotherapy directly to HER2-positive tumor cells, while olaparib blocks DNA repair in cancer ce…

This study tests a new drug called rezatapopt (PC14586) in people with advanced solid tumors that have a specific TP53 Y220C mutation. The drug is designed to reactivate the p53 protein, which normally helps stop cancer growth. The trial will also test rezatapopt combined with th…

This early-phase study tests an experimental drug called DM002 in about 160 people with advanced solid tumors (ovarian, prostate, endometrial, colorectal, or other solid cancers). The study has two parts: first, finding a safe dose by giving small groups gradually higher doses; s…

This phase 3 trial tests whether taking the drug olaparib for one year works as well as taking it for two years to keep ovarian cancer from coming back. The study includes 880 people with advanced ovarian cancer (stage III or IV) who have a BRCA mutation or similar DNA repair pro…

This Phase 3 trial tests a new oral drug, INCB123667, against standard chemotherapy in 466 people with platinum-resistant ovarian cancer that overexpresses cyclin E1. The goal is to see if the new drug can delay cancer growth or improve survival. Participants will be randomly ass…

This early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …

This large Phase 3 study tests a new medicine called Sofetabart Mipitecan for people with ovarian, fallopian tube, or peritoneal cancer. It includes two groups: those whose cancer stopped responding to platinum chemotherapy within six months (platinum-resistant), and those whose …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This phase II trial tests whether an IGFBP-2 vaccine, given after one dose of carboplatin, can stop ovarian cancer from growing in patients whose recurrence is detected only through a blood test. The vaccine helps the immune system target cancer cells, while carboplatin primes th…

This early-phase study tests a new drug called HWK-016 in people with advanced ovarian or endometrial cancers that have not responded to other treatments. The drug is designed to deliver a toxic payload directly to cancer cells that carry a specific marker (MUC16). The main goals…

This study tests a new drug called INCB123667 in 160 people with a type of ovarian cancer that no longer responds to platinum chemotherapy and has high levels of a protein called cyclin E1. The goal is to see if the drug can shrink tumors or slow the cancer's growth. Participants…

This early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …

This early-phase study tests a new drug called BGB-43395 in people with advanced HR+/HER2- breast cancer and other solid tumors. The drug blocks a protein (CDK4) that helps cancer cells grow. Researchers want to find the safest and most effective dose, either alone or combined wi…

This study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …

This early-phase trial is testing a new drug called AZD8421, alone or with other cancer drugs, in people with advanced ER+ breast cancer or high-grade ovarian cancer. The study aims to find safe doses and see if the drug can shrink tumors. About 564 women aged 18 and older will t…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…

This early-stage study tests a new drug called HWK-007 in people with advanced solid tumors, including certain ovarian, endometrial, and lung cancers. The drug is designed to target a protein (PTK7) found on cancer cells and deliver a chemotherapy-like payload directly to them. T…

This study tests a new drug called BI 3820768 in adults with advanced germ cell tumors, endometrial cancer, or ovarian cancer who have run out of treatment options. The drug aims to help the immune system fight cancer. Researchers will give increasing doses to find a safe amount …

This study looks at how hormone replacement therapy (HRT) affects adolescents aged 11-19 with premature ovarian insufficiency (POI), a condition where ovaries stop working before age 40. Participants receive estrogen patches and progesterone pills over 2 years, with regular check…

This study looks at how well women of African ancestry with ovarian cancer tolerate a maintenance drug called niraparib after initial treatment. Researchers want to see if genetic or environmental factors affect side effects and how the drug works. About 70 women will take nirapa…

This early-stage trial tests a new drug called LY4052031, which is designed to deliver a cancer-killing agent directly to tumor cells that have a protein called Nectin-4. The study includes 420 adults with advanced or metastatic solid tumors such as bladder, breast, lung, and oth…

This large Phase 3 trial will test a new drug called Rina-S, alone or with bevacizumab, against standard platinum-based chemotherapy for women with ovarian cancer that has returned after initial treatment. About 688 participants will be randomly assigned to receive either the new…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This study tests a new drug, Rina-S, in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to see if Rina-S is safe and how well it works against cancers like ovarian, lung, and breast cancer. About 884 participants will receive the dru…

This phase 3 trial tests whether adding a gene therapy called IMNN-001 (given into the abdomen) to standard chemotherapy helps people with advanced ovarian, fallopian tube, or peritoneal cancer live longer. About 500 newly diagnosed patients will be randomly assigned to receive e…

This Phase 3 trial tests whether adding the experimental drug Rina-S to standard care (bevacizumab or monitoring) can help keep platinum-sensitive ovarian cancer from returning after chemotherapy. About 528 participants will receive either Rina-S alone, Rina-S plus bevacizumab, b…

This study tests whether adding the experimental drug IMNN-001 to standard chemotherapy and bevacizumab can better eliminate remaining cancer in people with newly diagnosed advanced ovarian, fallopian tube, or primary peritoneal cancer. About 30 participants will be randomly assi…

This Phase 2 trial tests mirvetuximab soravtansine, a targeted drug, combined with standard chemotherapy (carboplatin) or bevacizumab in 400 people with a specific type of ovarian cancer (FRα-positive). The study aims to find the best dose and combination to shrink tumors and con…

This phase 3 trial tests whether a denser weekly chemotherapy schedule (carboplatin every 3 weeks plus weekly paclitaxel) can help ovarian cancer patients whose tumors are not responding well to standard treatment. The study enrolls 250 adults with advanced ovarian cancer who hav…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…

This study tests a traditional Chinese medicine called Yulinzhu in 60 women aged 18-40 with diminished ovarian reserve (low egg supply). Participants take the herbal therapy for 12 weeks, and researchers measure changes in hormone levels and egg count. The goal is to see if the t…

This early-stage trial is testing an experimental oral drug called OATD-02 in people with advanced or metastatic colorectal, ovarian, pancreatic, or renal cell cancer. The goal is to see if the drug is safe and whether it can help the immune system attack tumors by increasing arg…

This study tests whether a daily pill called isoquercetin, made from a plant compound, can reduce blood markers linked to clot risk in people with ovarian cancer. About 90 participants receiving chemotherapy will take either isoquercetin or a placebo for up to 6 weeks. The goal i…

This study tests whether giving heated chemotherapy directly into the abdomen during surgery is safe for women aged 70 and older with advanced ovarian cancer. The treatment, called NIPEC with carboplatin, is delivered at normal body temperature for 90 minutes right after the surg…

This study tests whether women with advanced ovarian cancer who have had all visible tumor removed can safely receive only 3 cycles of chemotherapy instead of the standard 6, followed by a maintenance drug called niraparib. The goal is to see if the shorter chemo is just as effec…

This early-phase trial tests whether adding the drug lurbinectedin to two standard chemotherapy drugs (paclitaxel and bevacizumab) can better control platinum-resistant ovarian cancer. About 34 adults with advanced ovarian, fallopian tube, or peritoneal cancer will receive the co…

This early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…

This early-phase trial is testing an experimental oral drug called APG-2449 in people with advanced solid tumors, including certain lung cancers, mesothelioma, esophageal cancer, and ovarian cancer. APG-2449 is designed to block several proteins (FAK, ALK, and ROS1) that help can…

This study is testing a new drug called ubamatamab, given alone or with another drug called cemiplimab, in people with ovarian cancer or other cancers that have come back after treatment. The main goals are to check safety, find the right dose, and see if the drugs can shrink tum…

This early-phase trial is testing an experimental oral drug called RGT-490 in about 63 adults with advanced solid tumors (including certain breast, ovarian, and endometrial cancers) that have a PIK3CA gene mutation and have stopped responding to standard treatments. The main goal…

This phase 3 study tests a new weekly growth hormone injection (inpegsomatropin) against an existing one (givopegsomatropin) in 84 girls with Turner syndrome who have short stature. The goal is to see which works better for increasing growth over 52 weeks. Participants are prepub…

This early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…

This study tests whether a program of exercise and nutrition counseling helps women with ovarian or endometrial cancer stick with their chemotherapy plan. About 200 women who are about to start chemotherapy will be randomly assigned to either receive weekly coaching sessions on p…

This study tests a combination of three drugs (avutometinib, defactinib, and letrozole) in 20 women with low-grade serous ovarian cancer who cannot have surgery right away. The goal is to see if the drugs can shrink tumors or control the cancer. Researchers will also monitor side…

This phase II trial tests the drug abemaciclib in people whose ovarian or endometrial cancer has returned and whose tumors have a specific genetic change (CDK4/6 pathway activation). Abemaciclib is a pill that blocks certain enzymes that cancer cells need to grow. The study will …

This study tests an experimental drug called Tulmimetostat (DZR123) in people with advanced solid tumors or lymphomas that have not improved with standard treatments. The drug is taken as a daily pill, either alone or combined with another drug (enzalutamide) for certain prostate…

This trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…

This early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…

This early-stage trial tests an investigational drug called ABBV-901, alone or with a standard drug bevacizumab, in about 219 adults with advanced ovarian cancer that no longer responds to platinum chemotherapy. The main goals are to check safety and see if the drug can shrink tu…

This study tests a new drug called mocertatug rezetecan (Mo-Rez) in 450 people with ovarian cancer that has stopped responding to platinum chemotherapy. The goal is to see if Mo-Rez helps people live longer without their cancer growing compared to standard treatments. Researchers…

This study looks at whether dydrogesterone, a hormone pill, works better than a common birth control pill (drospirenone and ethinylestradiol) for treating irregular, heavy, or prolonged periods in teenagers aged 10 to 19. The main goal is to see how many teens have normal cycles …

This study tests whether adding an experimental drug called TORL-1-23 to standard chemotherapy before surgery can help women with advanced ovarian cancer. About 60 participants with a specific tumor marker (CLDN6) will receive the combination, then undergo surgery. The goal is to…

This phase 2 trial investigates whether adding stereotactic body radiotherapy (SBRT) to the PARP inhibitor niraparib can improve control of ovarian cancer that has spread to a limited number of new spots after prior PARP inhibitor therapy. Participants will receive SBRT alone or …

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This early-stage trial tests an investigational drug called NTB-928 in women with ovarian cancer that has come back or no longer responds to standard treatments. NTB-928 is designed to direct the body's immune T cells to attack cancer cells by targeting a protein called FRα. The …

This study tests whether transplanting a woman's own previously frozen ovarian tissue can restore fertility and normal hormone levels after chemotherapy or radiation caused ovarian failure. Five women who had ovarian tissue frozen before cancer treatment will receive the tissue b…

This trial investigates whether infusing a woman's own platelet-rich plasma (PRP) into her ovaries can improve egg production and hormone levels in those with poor ovarian response to fertility treatments. The study involves 100 women who have had difficulty producing enough eggs…

This study investigates whether injecting a woman's own platelet-rich plasma (PRP) into her ovaries can improve egg production and hormone levels. It includes women aged 40 and older who have a poor response to standard fertility treatments. Participants receive either PRP or a p…

This trial tests a new experimental drug called CPI-0209 (Tulmimetostat) combined with the chemotherapy drug carboplatin in women whose ovarian cancer has returned but still responds to platinum-based treatments. The study aims to find the safest dose of CPI-0209 when given with …

This trial investigates whether injecting a woman's own platelet-rich plasma (PRP) into her ovaries can restart menstrual cycles and improve hormone levels. It includes 100 women under 40 with premature ovarian failure (early menopause). Participants receive either PRP or a place…

This study tests whether injecting a woman's own platelet-rich plasma (PRP) or platelet-free plasma (PFP) into her ovaries can restart menstrual cycles and improve hormone levels. The trial includes 100 women aged 45-55 who have been in menopause for at least a year. Researchers …

This Phase 3 trial tests a new drug called BL-B01D1 against standard chemotherapy in 384 women with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatment. The goal is to see if BL-B01D1 can slow disease progression and impro…

This study is testing an experimental oral drug called ATX-295 in people with advanced solid tumors, including ovarian cancer, that have not responded to standard treatments. The main goal is to find a safe and tolerable dose and to see if the drug can shrink tumors. About 90 par…

This early-phase trial is testing how the antifungal drug itraconazole affects the levels of a new cancer drug, AZD5335, in the body. The study involves 24 people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum chemotherapy. The goal is …

This study tests a new drug called ASP546C in people with advanced stomach, gastroesophageal junction, pancreatic, or certain other solid tumors. The drug is given as an infusion every 3 weeks. The study has two parts: Part 1 finds the best dose in stomach/GEJ cancer patients, an…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This trial tests whether placing a surgical mesh during abdominal closure can prevent incisional hernias in women undergoing ovarian cancer surgery. It also examines if a negative pressure wound dressing reduces infection risk. Participants are randomly assigned to one of four gr…

This phase 2 trial tests whether adding propranolol, a widely used beta-blocker, to standard chemotherapy before surgery can improve outcomes for women with advanced high-grade serous ovarian cancer. Participants receive propranolol pills alongside paclitaxel and carboplatin, fol…

This phase 2 trial is testing a combination of three drugs (carboplatin, paclitaxel, and pembrolizumab) given before surgery to shrink tumors in women with newly diagnosed stage III or IV ovarian cancer. After surgery, participants receive two maintenance drugs (olaparib and pemb…

This trial investigates whether giving back a patient's own blood stem cells after chemotherapy can help their bone marrow recover faster. The study includes women aged 18–60 with recurrent or metastatic ovarian cancer who are scheduled for chemotherapy. The goal is to reduce sev…

This phase 2 trial is testing a combination of three drugs—ipalotinib, sunitinib, and olaparib—given before surgery to people with a specific type of advanced ovarian cancer (HRD-positive). The goal is to shrink tumors enough to allow complete removal during surgery. The study wi…

This early-phase trial is testing whether specially engineered immune cells (OC-CTLs) can safely fight ovarian cancer. Twenty women with advanced-stage disease will receive 2 to 4 infusions of these cells. Researchers will monitor side effects and check if tumors shrink or stabil…

This early-stage trial tests an experimental drug called mocertatug rezetecan in 675 adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to deliver a toxin directly to cancer cells. The main goals are to check safety, find the ri…

This early-stage trial is testing a new treatment called GB-5267 for people with ovarian cancer that no longer responds to platinum-based chemotherapy. GB-5267 is a type of immune cell therapy (CAR T cell) that has been engineered to better target cancer cells and includes an ext…

This phase 2 trial is testing a combination of two drugs—vismodegib and atezolizumab—in people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if the combination is safe and can shrink tumor…

This phase 2 trial tests whether combining two oral drugs—ZEN003694 (a BET inhibitor) and talazoparib (a PARP inhibitor)—can shrink tumors in people with recurrent ovarian, fallopian tube, or primary peritoneal cancer. Participants must have already received a PARP inhibitor befo…

This Phase 2 trial tests whether adding the experimental drug ONC201 to standard chemotherapy (paclitaxel) can help women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 62 participants will receive the combinatio…

This early-phase study is testing an experimental drug called IDE034 in 150 adults with advanced solid tumors (such as lung, ovarian, or colorectal cancer) that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see …

This early-phase trial tests a new type of immune cell therapy called CIML NK cells in 18 people with recurrent ovarian cancer that no longer responds to standard chemotherapy. The cells are taken from the patient, trained in a lab to better attack cancer, and then infused into t…

This early-stage trial is testing whether a patient's own tumor-fighting immune cells (called TILs) can be safely used to treat recurrent ovarian cancer. Researchers take a sample of the tumor, grow the immune cells in a lab, and then inject them back into the patient. Only 6 peo…

This study tests a new drug called IMP1734 in people with advanced solid tumors (breast, ovarian, or prostate cancer) that have not responded to prior treatments. The main goals are to check safety, find the right dose, and see if it shrinks tumors. About 156 participants will ta…

This early-stage trial is testing a new drug called XmAb541 in people with advanced ovarian, endometrial, or germ cell tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and to find the best dose. About 282 participants will receive…

This early-phase study tests a new drug called CT-95 in people with advanced cancers that have a protein called mesothelin on their cells. The main goals are to find a safe dose and see if the drug can shrink tumors. About 70 adults with ovarian, lung, pancreatic, or other mesoth…

This study tests a new treatment using a patient's own immune cells, called CAR T cells, that are specially designed to target and kill solid tumor cells while leaving healthy cells unharmed. It is for adults with certain advanced cancers, including lung, colon, pancreatic, ovari…

This early-stage trial is testing an experimental oral drug called EXS74539 (REC-4539) in about 40 people with various solid tumors, including lung, prostate, ovarian, and breast cancers. The main goal is to check the drug's safety, find the right dose, and see how the body proce…

This study tests a new drug called INV-8989 in people with advanced solid tumors that have a specific genetic change called KRAS G12D. The trial has two phases: the first finds the safest dose, and the second checks how well the drug shrinks tumors. About 178 adults with cancers …

This early-phase trial is testing an experimental drug called CX-5461 (Pidnarulex) in people with advanced solid tumors (pancreatic, prostate, breast, or ovarian) that have specific BRCA2 or PALB2 gene mutations. The main goal is to find a safe and tolerable dose for future studi…

This study tests whether a traditional Chinese herbal formula (Bu Shen Yi Qi) combined with the hormone DHEA can improve ovarian function in women with diminished ovarian reserve. 74 women aged 20-40 will receive either the herbal formula plus DHEA or a placebo plus DHEA for 12 w…

This clinical trial is testing whether a combination of two drugs—dostarlimab (an immunotherapy) and niraparib (a PARP inhibitor)—works better than standard chemotherapy for women with a rare and aggressive type of uterine or ovarian cancer called carcinosarcoma. The study will e…

This study compares a new barbed suture (SYMMCORA) with a standard one (V-Loc) for closing the vaginal cuff after laparoscopic hysterectomy. The goal is to see if the new suture reduces stitching time without increasing complications. About 132 women having elective laparoscopic …

This study looks at two different surgeries for advanced ovarian cancer that has spread to the bowel. One method removes only the tumor from the bowel, while the other removes a piece of the bowel along with the tumor. The goal is to see which approach helps patients live longer …

This study tests a new treatment using specially designed immune cells (CAR-NK cells) that target two cancer markers at once. It is for people with ovarian, peritoneal, or fallopian tube cancer that has come back or not responded to standard treatments. The therapy is personalize…

This study tests an experimental drug called INV-6452 in adults with advanced breast cancer (HR+/HER2-) or other solid tumors that have stopped responding to standard treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 201 participants wil…

This early-stage study tests a new treatment called ZI-MA4-1, made from specially engineered immune cells, in people with advanced ovarian, lung, sarcoma, or head and neck cancers that have not responded to other therapies. The treatment aims to help the body's immune system atta…

This early-stage trial tests a new drug called HLX316 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to help the immune system attack cancer cells. The study will check for safety, side effects, and whether the drug can s…

This study tests a new drug called BC3195 combined with pembrolizumab (an immunotherapy) in people with advanced solid tumors that have spread. The goal is to find a safe dose and see if the combination can shrink tumors. About 111 adults with certain cancers will take part.

This study is for women with advanced ovarian, fallopian tube, or peritoneal cancer whose tumors did not shrink enough with standard chemotherapy. Researchers are testing a new method called PIPAC, which delivers chemotherapy as a pressurized spray directly into the abdomen, comb…

This study tests an experimental oral drug, JAB-30355, in adults with advanced solid tumors that have a specific change in the TP53 gene (called Y220C). The trial aims to find a safe dose and see if the drug can shrink tumors. About 144 participants who have already tried at leas…

This study tests whether using a fluorescent dye and special camera during ovarian cancer surgery can help surgeons see blood flow in the bowel and reduce the risk of leaks after reconnecting it. About 310 women with ovarian cancer who need bowel surgery will be randomly assigned…

This study tests a single injection of Radspherin®, a radioactive treatment given directly into the abdomen, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has spread to the lining of the belly. About 114 participants will receive either stand…

This phase 3 trial tests whether a new immunotherapy drug (QL1706) combined with bevacizumab can slow cancer growth better than standard chemotherapy in women with advanced ovarian clear cell carcinoma. About 226 participants will be randomly assigned to receive either the experi…

This study is for adults with certain cancers (like breast, lung, or ovarian) that are in complete remission but have persistently low platelet counts from past chemotherapy. It tests whether adding a vitamin A derivative (ATRA) to a standard platelet-boosting drug works better t…

This early-stage trial tests a new treatment called EB-DUALNK for adults with ovarian cancer that has come back or not responded to standard therapies. The treatment uses specially designed natural killer (NK) cells that target two markers on cancer cells. After a short course of…

This study tests vosoritide, a protein that stimulates bone growth, in 30 children with Noonan syndrome who are not growing well despite growth hormone treatment. The goal is to see if vosoritide can safely increase their growth rate over six months. Participants will receive one…

This pilot study tests whether adding the blood thinner tinzaparin to standard chemotherapy can improve outcomes for women with advanced ovarian cancer. About 40 participants will receive either chemotherapy plus tinzaparin or chemotherapy alone. The main goal is to see if tinzap…

This study compares a new method called PIPAC, which delivers chemotherapy as a spray inside the abdomen, to standard treatment for advanced ovarian cancer. The goal is to see if PIPAC can better reduce the cancer before surgery. About 60 adults with stage IIIC-IVA ovarian cancer…

This study tests an experimental drug called SKB518, given alone or with chemotherapy, in 280 people with advanced ovarian, cervical, or endometrial cancers. The goal is to see if the drug can shrink tumors or slow cancer growth. Researchers will also monitor side effects.

This early-phase trial tests a new drug, UCB4594, in people with advanced solid tumors that haven't responded to standard treatments. The drug is a monoclonal antibody that targets a protein called HLA-G on cancer cells, potentially helping the immune system attack them. The stud…

This study is for people with relapsed germ cell tumors (a type of cancer often in the testicles or ovaries) who have already had high-dose chemotherapy and a stem cell transplant. It tests whether taking a daily oral chemotherapy drug called etoposide for a while after treatment…

This study looks at whether removing enlarged lymph nodes in the chest area during surgery can help people with advanced ovarian cancer live longer without the cancer coming back. About 52 women with stage III or IV ovarian cancer will take part. The goal is to see if this extra …

This study tests whether a new version of the drug olaparib (DWZ2501) works as well as the current version (DWC202510) in women with advanced BRCA-mutated ovarian cancer. About 40 participants will take both versions at different times to compare drug levels and safety. The goal …

This phase II trial is testing whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, can control recurrent gynecological clear cell carcinoma better than standard chemotherapy. About 198 women with this rare cancer type will be randomly assigned to one o…

This study tests whether adding the experimental drug B013 to standard chemotherapy (paclitaxel) can help people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 90 participants will receive either the comb…

This study tests a new drug called IN10018 combined with standard chemotherapy in people with a tough-to-treat type of ovarian cancer that no longer responds to platinum-based drugs. About 150 adults will take part to see if the combination is safe and shrinks tumors. The goal is…

This phase 2 trial is testing two drugs, abemaciclib and letrozole, in 100 people with rare estrogen receptor-positive ovarian cancers (low grade serous carcinoma or granulosa cell tumors). The goal is to see if the combination can shrink tumors and control the disease. Participa…

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This study looks at two different surgical methods for removing simple ovarian cysts in girls and teens. The goal is to find out which technique better preserves the ovary's egg supply and lowers the chance of the cyst coming back. About 80 participants aged 1 to 18 with cysts 4 …

This phase 2 trial is testing valemetostat, a daily pill, in 900 adults with advanced solid tumors that have specific gene changes (like SMARCB1 or ARID1A). The drug works by blocking EZH1/2 enzymes to reactivate genes that normally protect against cancer. The main goal is to see…

This study tests a drug called HLX43 in 190 people with advanced cervical or ovarian cancer that came back or spread after initial treatment. HLX43 is designed to deliver a toxin directly to cancer cells by targeting a protein called PD-L1. The goal is to see if it can shrink tum…

This early-phase trial tests an experimental drug called GTB-5550 in adults with advanced solid tumors that have stopped responding to standard treatments. The drug is a nanobody designed to bridge natural killer cells to cancer cells, helping the immune system attack the tumor. …

This phase 3 trial tests a new drug called SHR-A1811 against standard chemotherapy in 300 people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based treatment. The goal is to see if the new drug can slow cancer growth and improve s…

This Phase 2 trial tests whether trastuzumab deruxtecan (T-DXd), a targeted antibody-drug conjugate, works better than standard chemotherapy for recurrent ovarian cancer that has stopped responding to PARP inhibitors. About 116 participants whose tumors express the HER2 protein w…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This phase 3 trial tests whether giving heated chemotherapy directly into the abdomen during surgery helps people with advanced ovarian, fallopian tube, or primary peritoneal cancer. About 220 participants will be randomly assigned to receive either heated chemo plus standard tre…

This study tests a new drug called XNW28012 in people with advanced solid tumors (pancreatic, ovarian, cervical, or colorectal cancers) that have stopped responding to standard treatments. The trial has two parts: first, finding a safe dose, then expanding to see if the drug shri…

This study tests a new treatment called GT307, which uses a patient's own immune cells (tumor-infiltrating lymphocytes) to fight advanced solid tumors like ovarian cancer. The goal is to see if it is safe and can shrink tumors. About 18 adults aged 18-70 with relapsed or metastat…

This study is for women with advanced ovarian cancer who have had complete surgery and chemotherapy. It compares two maintenance treatments: niraparib alone versus niraparib plus bevacizumab. The goal is to see which approach better delays cancer progression. About 390 participan…

This early-phase trial is testing a new approach to CAR-T cell therapy for adults with advanced solid tumors that have not responded to standard treatments. The therapy uses a patient's own immune cells, engineered to recognize two cancer-specific targets chosen based on each per…

This early-stage trial tests a new drug called QXL138AM in about 100 people with advanced solid tumors (like ovarian, pancreatic, or lung cancer) or multiple myeloma. The drug is designed to help the immune system attack cancer cells. The main goal is to check safety and find the…

This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, an…

This study tests if giving chemotherapy as a pressurized mist directly into the abdomen (PIPAC) alongside standard IV chemo can help more women with advanced ovarian cancer have successful tumor-removal surgery. It includes 160 women aged 18-75 with stage IIIB-IIIC disease. The g…

This early-phase study tests a new drug called azenosertib (ZN-c3) combined with standard chemotherapy or bevacizumab in people with ovarian, peritoneal, or fallopian tube cancer that has stopped responding to platinum-based treatment. About 172 participants will receive differen…

This early-phase trial is testing an investigational drug called SYS6043 in adults with advanced or metastatic solid tumors that have spread or no longer respond to standard treatments. The study aims to find a safe dose and watch for side effects, while also looking for early si…

This study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …

This early-phase trial is testing a new antibody drug called ZM008, first by itself and then together with another drug (toripalimab), in people with advanced solid tumors like lung, head and neck, and pancreatic cancers. The study aims to find a safe dose and see if the combinat…

This study tests whether an immunomodulatory drug (rituximab) can improve or normalize ovarian function in women aged 18-38 with autoimmune premature ovarian insufficiency (POI). Participants receive either rituximab or a placebo, and those who respond may undergo IVF. The goal i…

This study tests a technique called acute normovolemic hemodilution (ANH) in 86 women having surgery for advanced ovarian cancer. Before surgery, some blood is removed and stored, then returned during or after the operation. The goal is to see if this reduces the need for donor b…

This study tests a new drug called CapsuleX combined with cisplatin in 40 people whose ovarian cancer no longer responds to platinum-based chemotherapy. The goal is to see if the combination can shrink tumors and how safe it is. Participants must have confirmed ovarian, fallopian…

This study tests whether daphnetin capsules, made from a daphne plant extract, can improve outcomes when combined with standard chemotherapy (TC regimen) for stage III-IV epithelial ovarian cancer. About 98 participants who had initial surgery will receive the combination, then c…

This study tests a new drug called WJB001 combined with various chemotherapy drugs in people with advanced solid tumors that have not responded to standard treatments. The trial has three stages to find the safest dose, check how the body processes the drug, and see if it shrinks…

This early-phase study tests a new personalized cell therapy called Innocell for people with recurrent epithelial ovarian cancer. The treatment uses a patient's own tumor tissue to create a custom immunotherapy. The main goals are to see if it is safe to give and if the body's im…

This early-stage trial is testing a new daily oral medication called ETX-19477 in about 120 adults with advanced solid tumors, including breast, ovarian, prostate, and other cancers. The drug blocks a protein called PARG to interfere with cancer cells' ability to repair themselve…

This phase II trial compares the chemotherapy drugs trabectedin and gemcitabine in 100 people with advanced leiomyosarcoma that has worsened after initial treatment. The study aims to see which drug better delays cancer progression. It also includes an observational group for tho…

This early-stage trial is testing a virus called IVX037, which is injected directly into tumours to kill cancer cells. It is being studied alone and combined with an immunotherapy drug (sintilimab) in people with advanced colorectal, gastric, or ovarian cancers that have stopped …

This study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adul…

This study tests a new treatment using specially engineered natural killer (NK) cells to fight ovarian cancer that has come back or not responded to standard therapies. The treatment is personalized: each participant's tumor is checked for three markers, and they receive NK cells…

This study tests adding Ashwagandha (an herbal supplement) to standard chemotherapy (DOXIL) for people whose ovarian cancer has returned. The goal is to find a safe dose and see if the combination helps shrink tumors or slow cancer growth. About 72 participants with recurrent ova…

This study compares three surgical treatments for endometriomas (ovarian cysts from endometriosis) in 332 women aged 18-43 who want to become pregnant. Participants are randomly assigned to cystectomy, plasma vaporization, or sclerotherapy. The main goal is to see which approach …

This study tests a new treatment for advanced ovarian cancer patients who have a lot of fluid in their belly (ascites) and have not responded to standard therapies. The treatment involves injecting special immune cells called SK-NK cells directly into the abdomen once a week for …

This study tests whether a PARP inhibitor combined with bevacizumab (Avastin) can delay cancer recurrence in people with advanced ovarian, fallopian-tube, or primary peritoneal cancer that has a specific DNA repair defect (HRD). About 120 participants will receive chemotherapy pl…

This study tests a comprehensive fitness and nutrition program (prehabilitation) given before major cancer surgery. It includes 148 patients with pancreatic, ovarian, kidney, or bladder cancer who are frail or pre-frail. Some patients get the program alone, others get it with che…

This study compares two methods to prevent ovarian hyperstimulation syndrome (OHSS), a serious side effect of fertility treatments. About 150 women at high risk for OHSS will receive either cabergoline or a standard 'coasting' procedure. The goal is to see which approach better r…

This early-phase trial is testing the drug talazoparib together with radiation therapy in 24 women whose gynecologic cancer (ovarian, endometrial, cervical, or related cancers) has come back after previous treatment. Talazoparib blocks enzymes that cancer cells need to grow, and …

This study tests a new approach for advanced ovarian cancer. Patients take a targeted drug (olaparib) for a week before surgery, then receive heated chemotherapy directly in the abdomen during the operation. The goal is to see if this combination is safe and effective. The trial …

This early-phase study tests a new drug called PLB-002 in about 100 adults with advanced solid tumors that have not responded to other treatments. The main goals are to find a safe dose and understand side effects. PLB-002 is designed to target a protein (Claudin 6) found on some…

This phase 2 trial is testing two oral drugs, fuzuloparib and apatinib, given before surgery to women with a specific genetic type (HRD-positive) of advanced ovarian cancer. The goal is to shrink tumors enough for complete surgical removal, potentially improving outcomes and avoi…

This early-phase study tests a new treatment that combines specially grown immune cells (cCTL) with immunotherapy for people with advanced gynecologic cancers like ovarian, cervical, or endometrial cancer. The goal is to see if the combination is safe and can shrink tumors. About…

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This early-stage trial is testing a new drug called TORL-1-23 in about 90 people with advanced solid tumors, including ovarian, endometrial, and lung cancers. The drug is an antibody drug conjugate designed to target and kill cancer cells. The main goals are to check safety, find…

This Phase 3 trial tests whether adding heated chemotherapy (HIPEC) directly into the abdomen during surgery can help people with advanced ovarian cancer live longer. About 520 participants who have already had some chemo will be randomly assigned to get surgery with or without H…

This early trial tests a new treatment called SY001, which uses a patient's own immune cells (macrophages) engineered to attack cancer cells that have a protein called mesothelin. The study includes just 2 people with advanced ovarian or pancreatic cancer who have not responded t…

This early-phase trial is testing a new treatment called B7-H3 CAR T cells for adults with ovarian cancer that has come back and no longer responds to platinum chemotherapy. The treatment involves taking a patient's own immune cells, modifying them in a lab to better recognize an…

This study tests a new drug called SPR1020 in adults with advanced solid tumors that have not responded to standard treatments. The drug is designed to target cancer cells with specific genetic changes (BRCA or HRR mutations) and may also reach brain tumors. The goal is to find a…

This early-stage study is testing a new drug called AT03-65 in 83 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose, while also looking for early signs that the drug might shrink tumors. Part…

This study tests a new drug called IMC-R117C, alone or with other cancer drugs, in people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific genetic marker (HLA-A*02:01) and produce a protein called PIWIL1. The trial aims to find safe doses and…

This study tests whether adding the blood pressure drug telmisartan to standard chemotherapy can help people with ovarian cancer that no longer responds to platinum-based treatments. About 33 adults with this type of cancer will receive the combination, and researchers will measu…

This study tests whether a combination of light therapy on acupoints and a traditional Chinese medicine pill can improve ovarian function in women with diminished ovarian reserve (DOR). Ninety women aged 25-40 will be split into three groups: light plus placebo, light plus Chines…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer or other solid tumors that have spread or cannot be removed. The main goals are to check the drug's safety, find the best dose, and see if it helps shrink tumors. About 470 adults will tak…

This early-phase trial is testing a new drug, BC2027, in 180 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors or slow their growth. Participants re…

This study is testing an anti-PD-1 antibody (a type of immunotherapy) alone or combined with low-dose decitabine and/or standard chemotherapy in people whose cancers have come back or not responded to treatment. The trial includes patients with several cancer types, such as lymph…

This early-phase study tests a new drug called FORX-428 in about 40 adults with advanced solid tumors that have certain gene changes (like BRCA1/2 mutations). The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow their growth. …

This early-stage trial is testing an experimental drug called BL0175, a nano-medicine designed to deliver treatment directly into tumors. It is for postmenopausal women with advanced or metastatic hormone-receptor-positive breast, ovarian, or endometrial cancer that has progresse…

This study tests a new drug called JAB-8263 in adults with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 152 people will take part in this early-phase trial.

This early-stage trial is testing a new drug called DR-0202, a bispecific antibody, in people with advanced solid tumors (such as breast, lung, and pancreatic cancers) that have not responded to at least two prior treatments. The study aims to find a safe dose and see if the drug…

This phase 2 study is testing a combination of three drugs (disitamab vedotin, carboplatin, and bevacizumab) as first treatment and ongoing therapy for women with a specific type of advanced ovarian cancer that has a protein called HER2 and lacks a repair deficiency (HRD-negative…

This study tests whether early, personalized nutritional support and a simple home exercise program can prevent weight loss and improve quality of life in 200 adults with lung, colorectal, ovarian, or pancreatic cancer starting palliative chemotherapy. Participants receive guidan…

This study tests an experimental drug, YL205, in 252 people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is given by IV every three weeks. The main goals are to check safety, find the right dose, and see if it helps shrink tumors. This is …

This study looks at a treatment for large ovarian cysts caused by endometriosis (6 cm or bigger). The approach involves draining the cyst during a keyhole surgery and then using hormone therapy to lower the chance of the cyst coming back and to protect the ovaries. The goal is to…

This early-stage trial is testing a one-time treatment called OPB-101 for women with ovarian cancer that no longer responds to platinum chemotherapy. The therapy uses a patient's own immune cells (T cells) that are modified in a lab to better recognize and attack cancer cells, pl…

This phase 2 trial is testing whether a combination of two chemotherapy drugs (paclitaxel or nab-paclitaxel), an immunotherapy (pembrolizumab), and a bladder drug (mirabegron) can shrink tumors in people with ovarian cancer that has come back after initial treatment. About 20 adu…

This study tests a new treatment called GO306, a modified virus designed to infect and destroy cancer cells. It is for adults with advanced solid tumors (like breast, colon, or kidney cancer) that have not responded to standard therapies. The main goal is to check the safety of t…

This study tests a new combination of drugs for people whose ovarian cancer has returned after standard treatment. The drugs include a dual-target immunotherapy (QL1706), chemotherapy, and an oral anti-angiogenic agent (anlotinib). The goal is to see if this combo can shrink tumo…

This study tests a new drug called HS-20089 against standard chemotherapy for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based treatments. About 468 participants will be randomly assigned to receive either HS-20089 or…

This early-phase study tests a new drug, LNCB74, in people with advanced solid tumors (ovarian, breast, endometrial, bile duct, or lung cancer) that have not responded to standard treatments. The drug is designed to deliver a cancer-killing agent directly to tumor cells. The main…

This study tests a new drug called distamab vedotin (RC48) combined with carboplatin for people with advanced ovarian cancer that has a specific protein called HER2. The goal is to see if this combination works better and causes fewer side effects than standard chemotherapy. Abou…

This early-phase trial tests a new therapy called NW-101C, which uses a patient's own immune cells (T cells) that have been genetically modified to recognize and attack cancer cells carrying a protein called PRAME. The study will enroll 24 adults with advanced solid tumors that h…

This study tests whether using the hormone dydrogesterone (taken as a pill) alongside standard fertility injections can help women with low ovarian reserve collect more eggs for IVF. The trial compares this approach to the usual GnRH antagonist protocol. Researchers will track pr…

This early-phase study tests a new treatment called GC203 TIL for people with advanced solid tumors (cancers in organs like the breast, lung, or gut) that have not responded to standard therapies. The treatment uses a patient's own immune cells, which are modified in a lab to bet…

This trial tests two drugs, trastuzumab and pertuzumab, already approved for breast cancer, in people with rare cancers that have a specific genetic change called HER2 amplification or mutation. About 30 adults and children with various rare or hard-to-treat cancers will receive …

This study tests a program called PROADAPT for women aged 70 and older with advanced ovarian cancer who need surgery. The program includes exercise, nutrition advice, education, and medication management before and after surgery. The goal is to see if it reduces serious complicat…

This study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy can improve outcomes for people with a rare and aggressive ovarian cancer called small cell ovarian carcinoma of hypercalcemic type. The trial aims to increase the chance of complete re…

This study tests a new drug called YL202 in people with advanced solid tumors, including lung, breast, and head/neck cancers. The goal is to see if the drug can shrink tumors and control the disease. About 200 participants will receive the drug, and researchers will monitor safet…

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This study tests whether a dietary supplement made from royal jelly (MRJPs) can improve ovarian function and the thickness of the uterine lining in women with diminished ovarian reserve or thin endometrium. Sixty-six women aged 20 to 45 will take either the supplement or a placeb…

This study tests if injecting alcohol into endometriosis-related ovarian cysts (sclerotherapy) can better preserve egg supply and reduce cyst return compared to standard surgical removal. Sixty women aged 18-40 with cysts at least 2 cm will be randomly assigned to one of the two …

This study is testing a surgery called hepato-celiac lymphadenectomy for people with advanced or recurrent ovarian cancer. The surgery removes lymph nodes near the liver and stomach that may contain cancer. The goal is to see if this extra step, along with standard tumor removal,…

This study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…

This study is testing whether an artificial intelligence (AI) tool called CAT-OV can accurately identify ovarian cancer on CT scans. Ovarian cancer is often found late, when it's harder to treat, and current screening methods aren't reliable enough. The AI is being trained and te…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …

This study tests a new radioactive tracer called [18F]FPyQCP for PET scans to see if it can better detect several cancers, including colorectal, ovarian, gastric, breast, and pancreatic. About 71 adults with these cancers will receive the tracer and have a PET/CT scan. The goal i…

This study is testing a new type of PET scan that uses special radioactive tracers to find and map solid tumors in the body. The tracers target a protein called Trop2, which is often found on cancer cells. Researchers will enroll 400 people with various cancers (including bladder…

This study tests a new radioactive imaging agent that targets a protein called MSLN, found on some cancer cells. Researchers will use PET scans to see if this agent can better detect and stage ovarian cancer, lung adenocarcinoma, and pancreatic cancer in 100 patients and healthy …

This study aims to improve how doctors tell the difference between borderline ovarian tumors and early-stage invasive ovarian cancer before surgery. Researchers will test a panel of nine blood-based biomarkers in 400 women with suspicious ovarian cysts. If successful, this could …

This study is testing a new imaging agent called 18F-T2, which is designed to highlight tumors that produce a protein called CAIX. About 200 adults with various cancers (like kidney, lung, or breast cancer) will receive an injection of 18F-T2 and then undergo a PET/CT scan. The g…

This study explores whether DNA from routine Pap smears can detect early signs of ovarian cancer in women with high-risk gene mutations. Researchers will compare genetic changes in Pap test samples with tissue removed during preventive surgery. If the method works, it could becom…

This study tests whether ultrasound images of healthy ovaries can predict if a woman carries a harmful BRCA gene mutation, which raises the risk of breast and ovarian cancers. Researchers will develop a computer model using thousands of images from women with known BRCA status. I…

This study aims to develop a screening test that uses a vaginal swab and blood sample to find DNA markers for endometrial, ovarian, and cervical cancers. Researchers at Mayo Clinic will enroll over 3,000 women to see if the test can accurately detect these cancers at an early sta…

The SENTRY study is testing whether changes in platelet RNA (a type of genetic material in blood cells) can help diagnose ovarian cancer early. Researchers will collect blood samples from 245 women—those with ovarian masses and healthy volunteers—to see if their new test can accu…

This study looks at whether the things people buy at stores—like pain relievers or digestive aids—could be early warning signs of cancer. Researchers will compare the shopping habits of 2900 people, some diagnosed with cancer and some not, to see if certain purchases happen more …

This study is testing whether a blood test that looks for tiny particles called extracellular vesicles can help detect ovarian cancer earlier. Researchers will collect blood from 1,500 postmenopausal women aged 50-74 in Queensland, Australia. The main goal is to see if the test i…

This study tests whether a specific ultrasound measurement can reliably detect superficial endometriosis on the uterosacral ligaments. Researchers will compare ultrasound findings with laparoscopic surgery results in 64 women undergoing gynecological surgery. If a clear cutoff th…

This study is testing a new platform that uses advanced testing to get a complete picture of a person's tumor. The goal is to see if this detailed information can help doctors choose better treatments for patients with high-risk cancers like leukemia, multiple myeloma, and pancre…

This pilot study is testing whether a combination of two dyes (technetium-99m albumin nanocolloid and indocyanine green) can accurately identify the first lymph node where ovarian cancer might spread. The goal is to improve surgical staging and potentially avoid removing many lym…

This study tests a new ultrasound technique called microvessel imaging (UMI) to see if it can better detect small blood vessels in ovarian lesions, which may indicate cancer. Forty women scheduled for ovarian surgery will receive both standard and UMI ultrasounds. Doctors will co…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early, detect any cancer left after treatment, and catch a relapse before it shows up on scans. The …

This study tests Cellvizio, a device that provides real-time, high-resolution views of tissues during gynecological surgery. Researchers want to see if it can help diagnose lesions and check surgical margins more accurately. The study will enroll 80 women undergoing laparoscopic …

This study is testing a new AI-powered blood test that looks at platelets and immune cells to find early signs of eight different cancers, including lung, breast, and pancreatic cancer. Researchers will collect blood samples from 6,000 adults aged 40 and older, both with and with…

This study tests a sentinel lymph node technique, where a small amount of radioactive tracer and dye is injected to find the first lymph nodes that might contain cancer. In 200 women with early-stage ovarian cancer, doctors will compare this method to the standard approach of rem…

This study tests whether artificial intelligence (AI) can analyze videos from a keyhole surgery (laparoscopy) to predict if ovarian cancer tumors can be completely removed. The goal is to help doctors choose the best treatment plan—surgery first or chemotherapy first—for each pat…

This study looks at two surgeries to reduce ovarian cancer risk in women with BRCA1 gene changes. One surgery removes only the fallopian tubes, while the other removes both tubes and ovaries. Researchers want to see if removing just the tubes works nearly as well at preventing ca…

This study tests whether adding a polygenic risk score (PRS) — a measure based on 313 genetic markers — to the standard CanRisk model can improve breast cancer risk prediction and prevention. About 100 women at increased risk will receive genetic counseling, a blood draw, and the…

This pilot study is testing whether eating fermented poi every day for four weeks can improve the gut health of pregnant women and lower their risk of developing gestational diabetes. Fifty pregnant women between 10 and 24 weeks will eat one pound of poi daily and receive nutriti…

This study looks at different preventive surgeries for women with gene mutations that raise their risk of ovarian cancer. Researchers want to see if removing the fallopian tubes first and delaying ovary removal works as well as standard surgery or close monitoring. About 480 wome…

This study offers free genetic testing to 5,000 women, trans men, and non-binary people with female reproductive organs, regardless of family history. The goal is to find hidden gene changes that raise the risk of breast, ovarian, bowel, and womb cancers. Participants use a smart…

This phase 2 trial tests whether drinking tart cherry juice can prevent nerve damage (neuropathy) caused by the chemotherapy drug paclitaxel in breast and ovarian cancer patients. About 86 participants will be randomly assigned to receive either a high or low dose of the juice du…

This phase 2 trial tests whether riluzole, a drug already approved for ALS, can prevent the cognitive problems (often called 'chemo brain') that many cancer patients face during chemotherapy. The study will enroll 24 adults with various cancers who are about to start chemotherapy…

This trial tests a blended e-health program designed to help women with breast or gynecologic cancer cope with fear of their cancer returning or worsening. The program combines remote group sessions with online modules that teach skills to manage unhelpful thoughts and promote he…

This phase 2 trial tests whether guarana, a natural supplement from the Amazon, can reduce fatigue in 86 people with neuroendocrine tumors or gynecologic cancers. Participants take either guarana or a placebo daily for up to 42 days, and researchers measure changes in fatigue usi…

This study looks at whether intermittent fasting (not eating for 16 hours a day, 5 days a week) is safe and doable for people with advanced ovarian cancer who are getting chemotherapy before surgery. Twenty participants will either follow the fasting schedule or standard diet adv…

This study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study tests a comprehensive yoga therapy program for women with advanced ovarian cancer who are scheduled for chemotherapy and surgery. The program includes dietary advice, movement, breathing exercises, and mental support. Researchers want to see if it is feasible and if it…

This trial tests whether a 10-session group program called Social Management Training can improve mental health, executive function, and social skills in adults aged 16 to 69 who have sex chromosome aneuploidies (extra or missing sex chromosomes). Participants complete questionna…

This study tests whether N-Acetyl-Cysteine (NAC), a supplement, can reduce chemotherapy-related cognitive impairment (often called 'chemo brain') in ovarian cancer patients. About 102 postmenopausal women with advanced ovarian cancer receiving platinum-based chemotherapy will tak…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This pilot study tests whether a combination of stress-reducing drugs (propranolol and etodolac) and mind-body techniques (resilience training and music therapy) can help women with advanced ovarian cancer feel less stress before, during, and after surgery. The study will enroll …

This study tests whether taking omega-3 fish oil capsules and doing simple resistance exercises with elastic bands can help cancer patients maintain muscle mass and strength. It involves 288 adults with various cancers who are at risk of muscle wasting. The goal is to improve phy…

This early-stage trial tests a new drug called GB18 in 18-36 cancer patients who are losing weight and appetite due to their illness (cachexia). The drug is given as a shot under the skin. The main goal is to check safety, but researchers will also see if it helps patients gain w…

This study tests a new program called EASE, which uses a simple writing exercise to help adults with advanced cancer manage their fear of the future and related trauma symptoms. The study will include 250 people with advanced solid tumors, glioblastoma, or certain ovarian or lung…

This study is testing whether a low dose of olanzapine, a drug usually used for mental health conditions, can prevent or treat the loss of appetite and weight that often happens in cancer patients receiving chemotherapy. About 100 adults with stomach or ovarian cancer will take t…

This study tests whether using cold wraps plus compression (cryocompression) on hands and feet during chemotherapy can reduce nerve damage (peripheral neuropathy) in people with gynecologic cancer. About 190 participants will be randomly assigned to receive either cryocompression…

This study tests whether a 4-week exercise program before surgery can reduce frailty and improve recovery in women with advanced ovarian cancer. Frailty affects about half of these patients and often leads to worse surgical outcomes and chemotherapy delays. The program includes l…

This study tests a personalized physical activity program for women over 60 with gynecologic cancers who are receiving chemotherapy or other systemic treatments. The program includes a wearable activity tracker and a smartphone app, plus optional features like an exercise partner…

This study tests whether a high-protein nutrition plan combined with resistance exercises, started weeks before surgery and continued for 24 weeks after, can help older adults with cancer preserve their physical function. The trial enrolls Veterans aged 55 and older with certain …

This study is creating and testing a nurse-led program for women who experience early menopause after cancer. The program includes personalized education, decision support, and skills to manage menopause symptoms. About 117 women who have completed cancer treatment will take part…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This early-phase study tests whether psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can reduce fear of cancer returning in 20 women with early-stage breast or ovarian cancer who are currently in remission. Participants receive a moderately high d…

This study compares giving cancer treatment at home versus in the clinic for people with advanced cancers. The goal is to see if home treatment reduces stress, financial burden, and improves overall experience. About 220 participants will be randomly assigned to receive their reg…

This study tests whether spraying a low-dose lidocaine solution under the diaphragm during single-incision laparoscopic surgery can reduce shoulder pain afterward. About 100 women having surgery for benign gynecological conditions like ovarian cysts or uterine fibroids will take …

This study tests a coaching program called POSTCARE-O for women with ovarian cancer who have finished their initial treatment. The program provides support during the transition to survivorship, focusing on quality of life and emotional well-being. 120 women will be randomly assi…

This study tests a 4-week online cognitive-behavioral therapy (CBT) program for women with BRCA1/2 mutations who have finished cancer treatment and still worry a lot about cancer coming back. Researchers will compare those who get therapy right away to those on a waitlist, measur…

This study tests whether live, group-based exercise classes held over Zoom can help cancer survivors increase their physical activity, improve fitness, and enhance quality of life. Researchers will randomly assign 300 cancer survivors to either live online classes or recorded exe…

This study looks at whether alternate day fasting (eating very little every other day) before chemotherapy can help reduce side effects and improve quality of life for women with ovarian, endometrial, or uterine cancer. About 30 women who have had surgery and are about to start c…

This study tests whether a program of exercise, nutrition advice, and mental support before surgery helps gynecological cancer patients recover faster and feel better. About 64 women with ovarian or endometrial cancer will be randomly assigned to either standard care or the preha…

This study tests whether adding a gentle electrical acupoint stimulation (TEAS) to a standard three-drug anti-nausea regimen can further reduce vomiting after laparoscopic surgery. Researchers will compare active TEAS to a sham (fake) version in 780 women at high risk for postope…

This study explores whether acupuncture can reduce nerve pain and numbness caused by chemotherapy in people with gynecologic, urologic, or rectal cancers. About 75 participants will be randomly assigned to receive real acupuncture, sham acupuncture, or usual care for 6 weeks. The…

This study tests whether a 16-week, virtually supervised exercise program can help patients with ovarian or endometrial cancer maintain leg function and reduce chemotherapy-induced nerve damage. Thirty patients who have had surgery and are starting first-line chemo will be assign…

This study tests whether a personalized physical activity program using a wearable device (like a Fitbit) can help people with ovarian or endometrial cancer exercise more and improve their quality of life. About 120 participants will either receive tailored activity goals and fee…

This study tests small hormone implants placed under the skin to relieve menopause symptoms like hot flashes, low mood, and sexual problems. It includes 140 women with natural menopause, early ovarian failure, or menopause from cervical cancer treatment. Researchers will check ho…

This study compares two different ovarian stimulation methods used in IVF to see which one patients prefer and tolerate better. Sixty women undergoing either fertility preservation or preimplantation genetic testing will try both methods in a crossover design. The main goal is to…

This study tests a short therapy program called CALM (Managing Cancer and Living Meaningfully) for people with advanced ovarian cancer. The goal is to see if it is practical and helpful for reducing stress and improving well-being. Fifty participants will attend 3 to 6 therapy se…

This study investigates whether measuring whole-body metabolism—how the body uses energy—can reflect the metabolic changes in ovarian tumors and predict how well patients respond to chemotherapy. Researchers will measure resting metabolic rate and other metabolic markers in women…

This study collects blood or cheek swab samples from 1,100 cancer patients at the National Cancer Institute to analyze genetic differences that may influence how their bodies process cancer treatments. The goal is to understand why some patients experience more side effects or le…

This study looks at whether freezing ovarian tissue can help preserve fertility in people aged 2-21 with conditions like Turner syndrome, galactosemia, or premature ovarian insufficiency. Participants may have surgery to remove and freeze a gonad, with a small piece used for rese…

This study looks at tumor samples from 2,100 Chinese patients with lung, gynecologic, bile duct, or bladder cancers. Researchers will compare different HER2 testing methods to see how well they agree with each other. The goal is to improve the accuracy of HER2 testing, which help…

This large screening trial enrolls up to 2,900 people with advanced solid tumors that have spread or not responded to standard treatment. Researchers use genetic tests on tumor samples to find specific mutations, then assign patients to treatment trials testing drug combinations …

This study gathers medical records and leftover tissue samples from up to 2,000 people with low-grade ovarian or peritoneal tumors. The goal is to create a detailed database that helps researchers learn more about these rare cancers and how they are treated. No new drugs or proce…

This study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…

This study aims to create a large genetic database of people with Turner syndrome, a rare condition where a person is missing all or part of an X chromosome. Researchers want to compare the genes of women with Turner syndrome who are fertile with those who are not. Up to 500 part…

This observational study will look at how ovarian cancer is currently treated in Brazil, including surgeries, chemotherapy, and genetic testing. Researchers will collect data from 250 patients to find what is working well and what needs improvement. The goal is to use these insig…

This study looks at a treatment called HIPEC, where heated chemotherapy is washed inside the abdomen after surgery to remove tumors. Researchers want to see if lab-grown tumor models can predict how well the chemotherapy works. Sixty adults with cancers that have spread to the ab…

This study surveys women under 40 with lupus who are starting cyclophosphamide, a drug that can damage ovaries and cause infertility. Some received an additional drug called GnRHa to protect their ovaries. Researchers will compare menstrual health and fertility between those who …

This study looks at how well different labs agree when testing for a protein called FRa in stored tumor samples from women with ovarian cancer. About 1,000 women's archived tissue will be tested, but no new treatments or visits are needed. The goal is to improve consistency of FR…

This study looks at tissue samples from 200 people with relapsed ovarian, fallopian tube, or primary peritoneal cancer to see how often a protein called folate receptor alpha (FRα) is present at high levels. The goal is to understand how common this protein is, which may help doc…

This study examines whether concentrating ovarian cancer surgery in specialized centers and changes in treatment during the COVID-19 pandemic affect how long patients live without their cancer returning. Researchers will follow about 200 women diagnosed with epithelial ovarian ca…

This study will test tumor samples from 350 adults with gynecological cancers (endometrial, ovarian, cervical, vulvar, and vaginal) to see how often they have high levels of the HER2 protein. Researchers will use two standard lab tests to measure HER2. The goal is to learn how co…

This study tracks the long-term safety and effectiveness of the growth hormone treatment Growtropin-II in children with short stature. It includes up to 5,000 children with growth hormone deficiency, idiopathic short stature, Turner syndrome, or those born small for gestational a…

This study looks at how deeply argon beam coagulation (a tool that uses ionized gas to seal tissue) penetrates the ovary during laparoscopic surgery for ovarian endometriomas. Researchers will apply the technique to the cyst surface before removing it, then examine the tissue und…

This study looks at how common menstrual cycle symptoms—like pain, mood changes, and bleeding patterns—relate to physical and mental health in Spanish women aged 18 to 45 who have natural periods. Researchers will use questionnaires and urine ovulation tests to track symptoms and…

This study is for adults with certain advanced solid tumors (non-small cell lung cancer, colorectal cancer, or ovarian cancer). Researchers want to find biological markers that show how the experimental drug SAR444881 works, alone or with cemiplimab. About 40 participants will re…

This study surveys 2,000 ovarian cancer survivors to identify their ongoing concerns and unmet needs after diagnosis. Participants complete a one-time survey about their experiences, and up to 40 will also take part in a follow-up interview. The goal is to understand what matters…

This study compares how laparoscopic removal of ovarian cysts affects ovarian reserve—a key measure of fertility potential—in women with endometriotic cysts versus non-endometriotic cysts. Researchers will measure levels of anti-Müllerian hormone (AMH) before and three months aft…

This study is for young adults (ages 21-45) who had certain cancers as teens or young adults. Researchers are adapting a program that helps survivors manage their health after cancer treatment. The goal is to see if this program improves survivors' confidence and ability to handl…

This study investigates clonal hematopoiesis (CH) — small mutations in blood cells that can arise naturally or after cancer treatment — in adults receiving chemotherapy or radiation for solid tumors like breast, lung, or colorectal cancer. Researchers will collect blood, saliva, …

This study explores whether a blood test that detects circulating tumor DNA (ctDNA) can help doctors personalize treatment for people with five types of advanced cancer: non-small cell lung cancer, gastrointestinal stromal tumors, colorectal cancer, biliary tract cancer, and ovar…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study tests a digital app called the Genetics Adviser for Mainstream Care (GA-Mainstream) that educates cancer patients about genetic testing and delivers their results. Researchers want to see if using the app reduces distress and improves the patient experience compared to…

This study looks at 100 women with very low ovarian reserve (fewer than 4 follicles) undergoing IVF. Researchers will measure the volume of each follicle just before the trigger shot that matures the eggs. They want to see if follicle volume is a better predictor of egg maturity …

This observational registry is gathering data from 500 adults whose gynecologic cancer has returned after prior radiation therapy. Doctors are using reirradiation or other ablative strategies as part of standard care, and the registry will track how well these treatments control …

This study looks at whether tracking FSH levels during ovarian stimulation can help predict how many eggs a woman will produce. Researchers will monitor 150 women undergoing IVF to find the ideal FSH range for better outcomes. The goal is to tailor hormone doses to each patient, …

This study tests whether giving gynecologic cancer patients a list of questions to ask their doctor improves their confidence, reduces distress, and builds trust. About 70 adults with newly diagnosed or suspected gynecologic cancer will either receive the question list or usual c…

This study tests a workshop called HOPE-C, designed to reduce burnout among doctors, nurses, and social workers who care for ovarian cancer patients. The workshop helps clinicians share their challenging stories and build peer support. Researchers will enroll 25 participants to s…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study follows 1080 women diagnosed with premature ovarian insufficiency (POI) before age 40. Researchers will track their health over time, including bone density, hormone levels, and mental well-being. The goal is to identify risk factors and understand how POI affects over…

This study looks at whether a family history screening program can help more women in rural public health clinics get tested for genetic risks linked to breast and ovarian cancer. About 3,200 women over age 25 will take part. The goal is to see if the program increases the number…

This pilot study is testing whether a 7-day integrative oncology retreat called 'Via Shalva' is practical and helpful for women who have finished primary treatment for breast or gynecologic cancer. Thirty participants will either attend the retreat or receive usual follow-up care…

This study aims to find women in Texas who are at risk for hereditary breast, ovarian, and colorectal cancers but have limited access to healthcare. Researchers will use mobile mammography units to offer genetic testing and counseling on the spot. Up to 1,000 women will provide a…

This study collects tumor and blood samples from 3,300 people at high genetic risk for breast, ovarian, and related cancers. Researchers want to learn how these cancers develop and how well treatments work. Participants include those with BRCA1/2 or other gene mutations, or a str…

This early-stage study tests a small implantable device that is placed directly into tumors to see how different drugs work against ovarian, fallopian tube, and peritoneal cancers. About 20 people with advanced cancer will receive the device during standard surgery. The goal is t…

This pilot study tests whether an AI-based system can help doctors better manage fluids and blood pressure during complex ovarian cancer surgery. The system uses special software to guide fluid infusions and predict drops in blood pressure. The goal is to reduce complications lik…

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This Swiss study is testing whether creating a detailed molecular profile of each patient's tumor can help doctors choose more effective treatments for advanced ovarian cancer. Sixty newly diagnosed patients will be randomly assigned to either standard care or a personalized trea…

This study follows 120 women aged 35-50 who are having their ovaries removed (oophorectomy) for non-cancer reasons. Researchers will track changes in quality of life, heart health, brain function, and body fat over one year. Some women may start hormone therapy as part of routine…

This study is collecting information from 30 patients with an extremely rare ovarian cancer called primary ovarian leiomyosarcoma. Researchers will look at past and new cases to find patterns in how the cancer is diagnosed and treated. The goal is to create better guidelines for …

This study takes tumor samples from people with triple-negative breast cancer, colorectal cancer, or ovarian cancer and grows them in mice. Researchers then test different drugs on these mouse tumors to see which ones might work best for each person. The goal is to provide person…

This study follows 200 women with gynecologic cancer and their partners to see how sexual function changes over time. Researchers use questionnaires at diagnosis, 6 months, and 12 months after treatment. The goal is to understand when sexual counseling might be most helpful, with…

This study is looking at how the immune system responds to breast and ovarian cancers. Researchers will analyze tumor and blood samples from 160 women before surgery to understand immune cell activity and find markers that might predict survival. The goal is to learn more about h…

This study is testing whether a blood test for circulating tumor DNA (ctDNA) can help predict how well PARP inhibitor maintenance therapy works in women with high-grade serous ovarian cancer. Researchers will collect blood samples before surgery, after chemotherapy, during target…

This study tests whether an artificial intelligence program called STIMAI® can help choose the best day to give the final 'trigger' shot in IVF, compared to doctors making the decision alone. About 644 women undergoing ovarian stimulation for IVF will be randomly assigned to eith…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study looks at 50 patients with ovarian cancer that has come back quickly (within 6 months). Researchers will track their health and survival to learn more about who responds best to treatment. The goal is to improve how doctors classify and care for these patients.

This study aims to collect and analyze genetic information from 300 Taiwanese women with ovarian cancer. Researchers will look at tumor samples and medical records to find gene changes linked to treatment response and survival. The goal is to build a database that helps develop p…

This study looks at whether a blue dye injected into the ovary can help doctors find the first lymph node where cancer might spread, instead of removing many lymph nodes. The goal is to see if this less invasive method works as well as standard surgery for early-stage ovarian can…

This study looks at 371 people with advanced ovarian, peritoneal, or fallopian tube cancer to find out what factors—like age, tumor type, and genetics—are linked to how long they live. Researchers will collect medical data and blood samples over two years. The goal is to build a …

This study will analyze the genes of 25,000 adults who have cancer or are at risk for it. Researchers will use advanced testing to find genetic changes linked to cancer and track health records over time. The goal is to learn more about cancer biology and discover new ways to per…

This study collects tumor, fluid, blood, and other samples from 350 ovarian cancer patients to find biological markers that predict how the disease will respond to treatment. Researchers will analyze genetic changes before and after therapy to understand why some cancers become r…

This study tests whether a computer-generated character (PERLA) can effectively educate cancer patients about genetic testing, compared to a human genetics counselor. Researchers will enroll 800 people with certain cancers, including breast, ovarian, pancreatic, and prostate canc…

This study aims to find genes that may cause infertility in people with non-obstructive azoospermia (low or no sperm) or primary ovarian insufficiency (early menopause). Researchers will collect saliva samples from 500 adults to look for genetic differences. No new treatments are…

This study is looking for better ways to predict who might develop or have a return of certain cancers, including breast, colon, ovarian, melanoma, and lung cancer. Researchers will collect blood samples from 850 participants to study genetic and other biological markers. The goa…

This study looks at how the uterus absorbs fluid during early pregnancy, which may affect fertility. Researchers will compare tissue samples from women with and without endometriosis or infertility. The goal is to understand the role of certain proteins in this process. No treatm…

This study follows 60 girls and women with classic galactosemia, a rare genetic condition that affects how the body processes sugar. Researchers want to understand why many develop early ovarian failure and how puberty progresses. By tracking hormone levels and growth, they hope …

This study is creating a new survey to better understand how cancer and its treatments affect daily life. Researchers will ask 1,000 adults with cancer about their quality of life over two years. The goal is to help doctors and families provide better support tailored to each pat…

This study is testing whether a polygenic risk score (PRS) — a calculation based on many small genetic variations — can help predict a woman's chance of developing ovarian cancer. Researchers will compare the PRS of 1,300 Italian women, half with ovarian cancer and half without. …

This study looks at whether MRI scans can help doctors predict which women with endometriosis will benefit from the drug dienogest. Researchers will follow 48 women aged 19-45 who are starting dienogest for the first time. By comparing MRI images before treatment with changes in …

This study follows 1,000 women newly diagnosed with epithelial ovarian cancer to see how their genetic makeup (BRCA and HRD status) influences their response to standard treatments. Researchers will track surgery outcomes, treatment response, and survival. The goal is to gather r…

This study follows 50 women aged 70 and older with advanced ovarian cancer who are starting PARP inhibitors for the first time. Researchers will track how much of the planned dose patients actually receive, and look at factors like age, genetics, and overall health that might aff…

This study is gathering information from 25 adults with breast, lung, ovarian, multiple myeloma, or acute myeloid leukemia who are on active treatment. Participants fill out a short online survey each week for at least 12 weeks to report how they are feeling. The goal is to build…

This study is testing whether a web and mobile phone program can help Hispanic women who have had breast, uterine, or ovarian cancer, along with their adult daughters, eat better and be more active. The program includes 8 online modules. The main goal is to see if the program is …

This study aims to understand why some ovarian cancer patients respond well to platinum-based chemotherapy for years, while others do not respond at all. Researchers will analyze genetic, clinical, and tissue samples from 55 patients treated at one center. The goal is to find dif…

This study is testing a new blood test that looks for tumor DNA (ctDNA) to see if it can find ovarian cancer coming back earlier than current methods like CT scans or CA-125 blood tests. About 30 women with advanced ovarian cancer will give blood samples over time during their fo…

This study is looking at immune markers in the blood of 300 women with ovarian cancer to see if they can predict how the disease will progress. It is an observational study, meaning no treatment is given. The goal is to better understand the role of the immune system in ovarian c…

This study looks at whether changes in a blood marker called CRP can help predict how well immunotherapy works in women with advanced gynecologic cancers (cervical, endometrial, ovarian, or vulvar). Researchers will track CRP levels in 120 women receiving immunotherapy plus chemo…

This study looks at the bacteria and natural chemicals in the vagina to see if they can help find ovarian cancer early. Healthy volunteers (people with ovaries but no cancer or genetic risk) will provide vaginal swabs and stool samples. Their samples will be compared to those fro…

This study collects tumor and blood samples from over 1,000 people with certain cancers (ovarian, breast, head and neck, cervical, vulva, and sarcoma). Researchers will analyze the samples to find links between genetic changes, the immune system, and how the cancer behaves. Parti…

This study follows 600 Japanese women who carry BRCA1 or BRCA2 gene changes to see how often they develop ovarian, fallopian tube, or peritoneal cancers. Participants are monitored over time, and researchers also check tissue samples from those who choose preventive surgery. The …

This study is a large German registry that will follow nearly 2,000 people with advanced ovarian or endometrial cancer. Researchers will collect information on the treatments patients actually receive, how their disease responds, and their quality of life. The goal is to understa…

This study aims to understand why people with Turner syndrome often lose their hearing. Researchers will look at genetic and epigenetic markers in 150 adults aged 18-60. Participants will have hearing, balance, blood, and imaging tests. The goal is to find new ways to treat or de…

This study is testing whether smartwatches and blood tests can measure how well children recover after surgery to remove a solid tumor. About 40 children and their caregivers will wear smartwatches and answer questionnaires before surgery and for up to a year after. Researchers w…

This study follows 93 women with Turner syndrome who wanted to become parents. Researchers will track how many succeeded through natural pregnancy, egg donation, or adoption. The goal is to understand the real-world chances of parenthood for these women.

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study looks at how early menopause (before age 45) affects the nerves that control blood pressure. Researchers will measure nerve activity and blood pressure in 160 women aged 35-70. The goal is to understand why these women may have higher blood pressure and find ways to he…

This study at Strasbourg University Hospital surveys 20 teenage girls (ages 11-18) with female hypogonadism and their parents to assess their knowledge of hormone replacement therapy. The goal is to identify gaps in understanding so that better educational workshops can be design…

This study looks at whether a special MRI scoring system called O-RADS can accurately tell if an ovarian mass in girls under 16 is cancerous or not. Researchers will review the MRIs of 100 girls who had surgery for ovarian masses at two hospitals. The goal is to see if this tool …

This study looks at how things in your environment—like pollution, chemicals, diet, and sleep—might affect your hormones and reproductive health. Researchers will follow 300 people aged 8 and older who have conditions like low or high hormone levels, early or late puberty, or inf…

This study compares two common risk assessment tools—the Charlson Comorbidity Index (CCI) and the POSSUM score—to see which better predicts complications in women undergoing surgery for gynecologic cancers. Researchers will track complications, hospital stay length, and 30-day de…

This study looks at how early menopause (premature ovarian insufficiency) affects the heart's electrical signals, which can raise the risk of dangerous heart rhythms. Researchers will compare 120 women with and without this condition, and also check how hormone replacement therap…

This study aims to learn how gene and protein changes in gynecologic tumors affect cancer behavior and treatment response. Researchers will collect tumor tissue and blood samples from 1,000 people with ovarian, uterine, cervical, or other gynecologic cancers. The goal is to bette…

This study collects blood, tumor tissue, and other fluids from people with advanced ovarian cancer to find biological markers (biomarkers). Researchers will analyze these samples to understand why some patients live longer or respond better to treatment. Results may be shared wit…

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study is looking at 60 women who are getting a hormone-releasing IUD (LNG-IUD) to see if the timing of insertion during their menstrual cycle affects whether they develop ovarian cysts. Researchers will use ultrasound to check for cysts at 0, 3, 6, and 12 months after insert…

This study tracks 100 cancer survivors aged 18–74 to see how common muscle loss (sarcopenia) and cognitive problems ('chemo brain') are after treatment. Participants undergo physical and mental assessments. The goal is to better understand these long-term side effects and guide p…

This study looks at the immune system in women with a new diagnosis of epithelial ovarian cancer. Researchers will collect tumor tissue, blood, and other samples to see how different immune cells relate to how long patients stay cancer-free. The goal is to learn more, not to test…